VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Verrica Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| License and collaboration revenue | $20.29M | $992.00K | – | – | 57.0% | +1945.6% |
| Product revenue, net | $15.29M | $6.57M | $4.66M | $0 | 43.0% | +132.5% |
| License and Collaboration Revenue, Commercial Supply and Development | $2.30M | $1.00M | – | – | 6.5% | +130.0% |
| Collaboration [Member] | – | $992.00K | $466.00K | $9.03M | – | – |
By region
From the segment and revenue-disaggregation notes of Verrica Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.